Cassava stocks are falling again, after Quanterix said it was “no” preparing data graphs submitted by cassava, which are in dispute

by

Quanterix Corp. QTRX;
+ 9.38%
said that while previously employed by Cassava Sciences Inc. SAVA,
-19.39%
to perform sample testing, the digitized biomarker analysis company said that, or its employees, “did not interpret the test results or prepare the data graphs” presented by Cassava at the International Conference on Biomarkers. ‘Alzheimer’s Association (AAIC) in July, or otherwise. Earlier this week, in response to a request from Cassava, the Food and Drug Administration stopped clinical trials on Cassava Alzheimer’s treatment due to concerns about the accuracy and integrity of the data. of biomarkers presented, Cassava had said that Quanterix generated data from Alzheimer’s patients. The news of the request for a halt had dropped Cassava’s shares by 39.9% in two days until Thursday. Shares of Quanterix fell 9.2% on Thursday, after losing 1.5% on Wednesday. In Friday’s statement, Quanterix said it is “widely recognized for its commitment to business integrity and the maintenance of the highest quality standards.” Quanterix shares rose 4.5% in premarket trading, while cassava shares fell 21.2%

.Source